ProstateSmart.info: Smart PSA Screening for Prostate Cancer
Incline Village, Nevada - January 28, 2018
Soar BioDynamics, Inc., is proud to announce its ProstateSmart.info website and analysis services for smart PSA screening for prostate cancer. Free, Economy and Premium smart PSA screening analysis services help men balance the risks of premature biopsy and late diagnosis of prostate cancer.
"Smart PSA screening for prostate cancer is better than no PSA screening and better than ordinary PSA screening." explained Tom Neville, PhD, founder and chief scientist. " No PSA screening can lead to regrets of late diagnosis and risk of prostate cancer death. Ordinary PSA screening can lead to regrets of premature biopsy triggered by an elevated PSA, over diagnosis, treatment and side effects, including impotence and incontinence. Smart PSA screening helps reduce the risks of both premature biopsy triggered by an elevated PSA and late diagnosis."
To learn more about smart PSA screening for prostate cancer, visit: https://www.prostatesmart.info
Smart PSA Screening for Prostate Cancer
Smart PSA screening for prostate cancer uses new screening technologies and analysis to help balance the risks of premature biopsy and the risks of late diagnosis. New prostate screening technologies include blood tests (PSA, Free PSA, PHI, 4Kscore) risk calculators, imaging (ultrasound and multi-parametric MRI) and biopsies (MRI targeted and conventional pattern). Smart screening analysis estimates the loss of life expectancy risk from delay and often allows men to become comfortable delaying a biopsy.
An elevated PSA test can trigger a premature biopsy with risk of sepsis (infection), over diagnosis and treatment with side effects. Biopsy delay is preferable for many men because their estimated loss of life expectancy from delay is often low - only a few weeks or months. Many men prefer biopsy delay because they are very concerned about disrupting their current high quality of life and much less concerned about the risk of losing a few weeks or months of life expectancy at the end of their life when they expect the quality to be low. Ordinary PSA screening and conventional biopsy thresholds can result in premature biopsy for many men.
Smart screening analysis estimates the risk of loss of life expectancy from delay for individual men based on results from new technologies. These estimates help men and their physicians decide if a biopsy is premature and determine when a biopsy might be justified based on the man's risk preferences.
About Soar BioDynamics, Inc.
Soar BioDynamics, Inc. does prostate cancer screening research and provides the ProstateSmart.info website and analysis services for smart PSA screening for prostate cancer. It was founded by Tom Neville, PhD, who is a prostate cancer survivor and Rhodes Scholar.
Tom Neville, PhD